Navigation Links
Isis Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Date:3/2/2010

CARLSBAD, Calif., March 2 /PRNewswire-FirstCall/ --Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen's 30th Annual Health Care Conference on Monday, March 8, 2010 at 2:30 p.m. ET at The Boston Marriott Copley Place.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.isispharm.com

'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
2. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2009 Financial Results
3. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
4. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
5. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
6. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
7. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
8. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
10. Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
11. Jiangbo Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... IRIDEX Corporation (NASDAQ: IRIX ) today ... common stock, $0.01 par value (the "Offering" with such shares ... final terms of the Offering will depend on market and ... be no assurance as to whether or when the Offering ... net proceeds it will receive from this offering for working ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY ... ... reducing loss of blood during surgeries, lowering the risks of ... decreasing risks of SSIs. The patient warming systems can be ... warming systems.These benefits in turn reduce the stay at hospitals ...
(Date:12/8/2016)... -- KEY FINDINGS The global medical lifting ... reasons for growth of the medical lifting sling market ... diseases, high recovery cost of injuries and government initiatives ... sling refers to an assistive device that helps caregiver ... to the lift and hold the patient. It is ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... the Pennsylvania Cable Network (PCN) during the summer of 2016. The program was ... provided by the United States Department of Health and Human Services Administration. ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance ... today for its 33rd Annual Issues & Research Conference, March 2-3, 2017, ... of the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ( ... patients about the safety issues related to dental restorations. According to the American Academy ... to reach $6.4 billion in 2018 with more than 30 million Americans missing all ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... access for customers and employees that are both engaging and easy to use. ... Smart Technology, the software company revealed today its plans to roll out new ...
Breaking Medicine News(10 mins):